LETKO, BROSSEAU & ASSOCIATES INC
Position in ELVN — Enliven Therapeutics, Inc.
CIK 1297496
MONTREAL, A8
Position in ELVN
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$376,320
New position
Shares Held
9,600
first reported quarter
Ownership
0.016%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026LETKO, BROSSEAU & ASSOCIATES INC holds $40,808,046 across 16 Biotechnology names. ELVN ranks #4 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
748,815 | $38,039,802 | |
| 2 | PVLA |
Palvella Therapeutics, Inc.
|
3,500 | $436,275 | |
| 3 | NAMS |
NewAmsterdam Pharma Co N.V.
|
11,775 | $376,917 | |
| 4 | ELVN |
Enliven Therapeutics, Inc.
This page
|
9,600 | $376,320 | |
| 5 | MGTX |
MeiraGTx Holdings plc
|
32,000 | $277,120 | |
| 6 | CABA |
Cabaletta Bio, Inc.
|
90,475 | $243,377 | |
| 7 | BCAX |
Bicara Therapeutics Inc.
|
11,175 | $222,270 | |
| 8 | SPRY |
ARS Pharmaceuticals, Inc.
|
24,700 | $198,341 |
All Filings in ELVN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $376,320 | 9,600 | Shares | Sole | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||